Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Alzheimer’s

Canadian charity aims to tackle stigma of dementia

Alzheimer Society launches campaign during its Alzheimer’s Awareness Month

Daiichi Sankyo launches Alzheimer’s campaign

Disease awareness drive will include TV commercials, newspaper adverts and a website

EISAI

Eisai forms neurology partnership with UCL

Unique ‘therapeutic innovation group’ will research Alzheimer's, Parkinson's and other brain conditions

- PMLiVE

Lilly plans another trial for Alzheimer’s hope solanezumab

Presses on with another late-stage study for the drug

Bristol-Myers Squibb (BMS) building

BMS ends development of Alzheimer’s candidate avagacestat

Amyloid-targeting candidate fails to make it to phase III trials

- PMLiVE

Merck & Co takes Alzheimer’s prospect into phase II/III trials

Developed to interrupt formation of amyloid plaques

- PMLiVE

Funding boost for late-stage tau-based Alzheimer’s research

Singapore company TauRx receives $112m investment to take LMTX treatment into phase III

- PMLiVE

Lilly, Roche drugs selected for Alzheimer’s prevention study

Large-scale study will involve Roche's gantenerumab and Lilly's solanezumab

- PMLiVE

Independent analysis raises hope for Lilly’s Alzheimer’s drug

Pooled results show solanezumab slowed cognitive decline in subgroup by 34 per cent

FDA sued for approving high dose of Eisai’s Alzheimer’s drug Aricept

Consumer rights group Public Citizen claims the high-strength dose is unsafe

- PMLiVE

Lilly’s Alzheimer’s drug solanezumab stumbles, but doesn’t fall in phase III

Fails to show significant benefit, but data holds some consolation

- PMLiVE

End of the line for intravenous bapineuzumab in Alzheimer’s

Negative trial results for Pfizer and Johnson & Johnson to concede defeat

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links